Eli Lilly And Company Announces New Phase 3b ADtouch Data Showing EBGLYSS Delivers Significant Improvements In Skin Clearance, Itch, Pain And Patient Satisfaction In Moderate-To-Severe Hand And Foot Atopic Dermatitis
Eli Lilly announced positive Phase 3b ADtouch trial results for EBGLYSS, showing significant improvements in hand and foot skin clearance, itch, pain, and patient satisfaction in moderate-to-severe atopic dermatitis. The trial met primary and secondary endpoints at Week 16, with patient-reported outcomes and quality of life improvements.
How this was made
The 30-second read
Why it matters
The trial results provide a new indication that could expand the drug's market size and support a label update, influencing Lilly's revenue outlook.
Market read
Positive Phase 3b data may lift Lilly's stock and affect the broader dermatology biotech space.
What to watch
Competition from other IL‑13 blockers and the modest adverse‑event profile may limit upside.
Background
EBGLYSS (lebrikizumab) is an IL‑13 inhibitor already approved for moderate‑to‑severe eczema; the new data target hand and foot involvement, a previously unmet need.
Ticker impact
Eli Lilly disclosed positive Phase 3b ADtouch trial results for EBGLYSS, meeting primary and secondary endpoints.
likely upward pressure as investors price in potential label expansion
First‑time disclosure of statistically significant efficacy and safety in hand/foot atopic dermatitis, with FDA submission planned.
Market effects
Strengthens the biotech/dermatology segment and may pressure peers developing IL‑13 inhibitors.
U.S. biotech equities could see modest gains.
Potential label update could affect global dermatology markets, especially where Almirall holds rights.
Counterpoint
If regulatory review raises safety concerns, the initial enthusiasm could reverse.
Key entities
- companyEli Lilly and Company
Pharmaceutical developer of EBGLYSS.
- companyAlmirall
European licensee for EBGLYSS.
